Janssen Pharmaceuticals Inc.

12/10/2019 | Press release | Distributed by Public on 12/11/2019 00:13

DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma